Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
WARREN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring...
Pharmaceutical
ORYZON to Provide Corporate Progress Updates at Several Events in May
Bio-Equity Europe 2024Asebio Investor Day 2024RSC Hot Topics: Covalent Drug DiscoveryForo Medcap BME 2024 MADRID, Spain and CAMBRIDGE, Mass., May...
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial...
Annexon Biosciences to Present at the Bank of America Health Care Conference
BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform...
IRLAB Enters a Development Collaboration for IRL757 as a Novel Treatment for Apathy
ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLYGOTHENBURG, SE / ACCESSWIRE / May 7, 2024...
Outcome Capital Continues to Expand with the Addition of Industry Veteran Stanislav Glezer, MD MBA
Dr. Glezer’s appointment as Managing Director will strengthen Outcome’s healthcare innovation and product launch expertiseBOSTON--(BUSINESS WIRE)--Outcome Capital, LLC, a highly...
TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors
– Accomplished industry veteran brings deep strategic and operational expertiseDENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating...
FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
TORONTO, ON / ACCESSWIRE / May 7, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
Ipsen S.A. – Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting
Information relating to the holding of the Combined Shareholders’ Meeting of 28 May 2024 of Ipsen S.A. Formalities...
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
- Interim data from SEAPORT-1, a Phase 1 trial of INZ-701 in patients with end-stage kidney disease receiving hemodialysis, on...
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
Company to host conference call to discuss financial results and provide a corporate update on May 13, 2024 at 4:30...
Scorpius Holdings Appoints New VP of Business Development Shari Udoff-McDonald
Biopharma industry veteran joins Scorpius’ leadership teamDURHAM, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX)...
Palisade Bio Appoints Margery Fischbein to its Board of Directors
Palisade Bio, Inc. Margery Fischbein Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing,...
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy
TARRYTOWN, New York, May 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (OTC:PXMD), a biopharmaceutical company focused on advancing...
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to...
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, a program granted Fast...
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and...
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
Investigational travatrelvir demonstrated preclinical activity against multiple SARS-CoV-2 variants Orally administered novel protease inhibitor does not require ritonavir co-administration First-in-Human...
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic...
Reflect Scientific Inc. Announces Second Quarter Sale of Groundbreaking Aerospace Manufacturing Solution
OREM, Utah, May 07, 2024 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a leading provider of innovative cooling solutions,...